Citations

Clear

1434 citation(s) found for "Uk, Nathan".

Racial and Ethnic Diversity of U.S. Residency Programs, 2011–2019
Hucko, Lauren , Dominguez, Johanny Lopez , Scott, Nathan L. , Williams, Basil K. , Fountain, Tamara R., Sridhar, Jayanth , Lopez Dominguez, Johanny, Al-khersan, Hasenin , Cavuoto, Kara M.

Mayo Clinic

New England Journal of Medicine | June 1, 2022 | Volume: 386 | Issue: 22 | Pages: 2152-2153

10.1056/nejmc2200107 | PMID 35648712 Get It

Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis
Samadder, N. Jewel , Foster, Nathan R. , Burke, Carol A. , Cruz‐Correa, Marcia , Mankaney, Gautam , Buttar, Navtej , Thirumurthi, Selvi , Turgeon, D. Kim , Sossenheimer, Michael, Westover, Michelle, Della’Zanna, Gary , Rodriguez, Luz M. , Szabó, Éva , Zahrieh, David M. , McMurray, Ryan P. , Cruz-Correa, Marcia , Vilar, Eduardo , Limburg, Paul J. , Szabo, Eva , Burke, Carol A , Stoffel, Elena M. , Kanth, Priyanka , Das, Rohit Kumar , Richmond, Ellen S. , Umar, Asad , RODRIGUEZ, LUZ MARIA

Mayo Clinic

Gut | May 30, 2022 | Volume: 72 | Issue: 2 | Pages: 256-263

10.1136/gutjnl-2021-326532 | PMID 35636921 Get It

Importance Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal adenomas and cancer. Combination sulindac and erlotinib was previously shown to reduce duodenal polyp burden but was associated with a relatively high adverse event (AE) rate. Objective: To evaluate if a once weekly dosing schedule for erlotinib intervention improves the AE profile, while still providing efficacy with respect to reduced polyp burden, in participants with FAP. Design, setting and participants: Single-arm trial, enrolling 46 participants with FAP, conducted from October 2017 to September 2019 in eight academic cancer centres. Exposures Participants self-administered 350 mg of erlotinib by mouth, one time per week for 6 months. Main outcomes and measures: Duodenal polyp burden (sum of polyp diameters) was assessed in the proximal duodenum by esophagogastroduodenoscopy performed at baseline and 6 months, with mean per cent change defined as the primary efficacy outcome of interest. Rate of grade 2–3 AEs was evaluated as a co-primary outcome. Secondary outcomes included changes in total duodenal polyp count, along with changes in lower gastrointestinal (GI) polyp burden and count (for participants examined by optional lower endoscopy). Results Forty-six participants (mean age, 44.1 years (range, 18–68); women, 22 (48%)) were enrolled; 42 participants completed 6 months of intervention and were included in the per-protocol analysis. Duodenal polyp burden was significantly reduced after 6 months of weekly erlotinib intervention, with a mean per cent change of −29.6% (95% CI, −39.6% to −19.7%; p<0.0001). Similar results were observed in subgroup analyses defined by participants with advanced duodenal polyposis (Spigelman 3) at baseline (mean, −27%; 95% CI, −38.7% to −15.2%; p<0.0001). Post-intervention Spigelman stage was downstaged in 12% of the participants. Lower GI polyp number was also decreased after 6 months of intervention (median, −30.8%; IQR, −47.4% to 0.0%; p=0.0256). Grade 2 or 3 AEs were reported in 71.7% of subjects, with only two experiencing grade 3 toxicity at least possibly related to intervention. Conclusion In this single-arm, multi-centre trial of participants with FAP, erlotinib one time per week resulted in markedly lower duodenal polyp burden, and modestly reduced lower GI polyp burden, after 6 months of intervention. While AEs were still reported by nearly three-quarters of all participants, these events were generally lower grade and well-tolerated. These findings support further investigation of erlotinib as an effective, acceptable cancer preventive agent for FAP-associated GI polyposis. Trial registration number NCT02961374 .
A stress-induced cilium-to-PML-NB route drives senescence initiation
Hu, Jinghua , Ma, Xiaoyu , Zhang, Yingyi , Zhao, Debiao , Kirkland, James L. , Chini, Eduardo N. , Ling, Kun , Zhang, Yingyi , Zhang, Yuanyuan , Zhang, Xu , Huang, Yan , He, Kai , Chen, Chuan , Hao, Jielu , LeBrasseur, Nathan K. , Wei, Qing

Mayo Clinic

No container title available | May 26, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1522828/v1 Get It

Abstract Cellular senescence contributes to tissue homeostasis and age-related pathologies. However, how senescence is initiated in damaged cells remains vague. Here, we discover that irreparable stresses induce transient biogenesis of cilia, which are used by stressed cells to directly communicate with the promyelocytic leukemia nuclear bodies (PML-NBs), the validated stress signaling hub, to initiate senescence responses. Mechanistically, a ciliary ARL13B-ARL3 GTPase cascade negatively regulates the association of transition fiber protein FBF1 and SUMO-conjugating enzyme UBC9. Irreparable stresses downregulate the ciliary ARLs to release UBC9, which SUMOylates FBF1 at the ciliary base. SUMOylated FBF1 then translocates to PML-NBs to promote PML-NB-dependent senescence initiation. Remarkably, Fbf1 suppression effectively subdues global senescence burden and prevents associated health-span decline in irradiation-treated mice. Collectively, our findings assign primary cilia a central role in inducing senescence program and identify them as promising targets to dampen senescence-associated detrimental damage in future senotherapy strategies.
Computed tomography measured tissue density of pectoral muscle and liver predicts outcomes in heart transplant recipients
Kuchnia, Adam J. , Lortie, Jevin , Osterbauer, Katie, Hess, Timothy , Stabo, Nicholas, Wheeler, Nathan , Binkley, Neil , Hermsen, Joshua L., Dhingra, Ravi , Tsuchiya, Nanae , François, Christopher J. , Schiebler, Mark

Mayo Clinic

JCSM Rapid Communications | May 26, 2022 | Volume: 5 | Issue: 2 | Pages: 171-181

10.1002/rco2.62 Get It

AbstractBackgroundComputed tomography (CT)‐derived measures of tissue quality can add to frailty assessment and improve selection of candidates for heart transplant. We investigated the prognostic value of CT measures of tissue density for predicting hospital length of stay (LOS) and mortality post‐transplant.MethodsAll patients at a quaternary care hospital between 1999 to 2018 with preheart transplant CT scans and available data on transplant outcomes were eligible (n = 189), including a subset within the total cohort with scans 6‐month pretransplant (n = 103). Axial chest CT scans were analysed for liver and muscle density at the 12th thoracic vertebrae and aortic arch landmarks, respectively. Cox and linear regression models examined the risk of death and LOS, respectively, according to median (above or below) pectoral muscle density. Low‐density muscle (LDM) area and liver density were analysed as continuous variables.ResultsOut of 157 patients with readable CT scans (median age 55 years, interquartile range [50–60] 10% women), 31 died on 1‐year follow up. Patients with higher than and at median pectoral muscle density (39.5 Hounsfield Unit [HU]) had better 1‐year survival in the overall cohort (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.673, 0.989; p = 0.039), with the 6‐month cohort showing a trend (HR 0.79, 95% CI 0.603, 1.023; p = 0.074) towards improved survival. Conversely, every 5‐cm2 increase in pectoral LDM area was associated with 2.4‐day lower LOS (p = 0.045) in the overall cohort, and a 2.6‐day lower LOS in the 6‐month cohort (p = 0.05). Patients with higher ratio of normal‐density muscle to LDM had higher LOS (p < 0.01). Every 5‐HU increase in liver density at a region of interest was associated with 0.24‐day higher post‐transplant LOS in the overall cohort, and a 0.41 higher LOS in the 6‐month cohort (p ≤ 0.05).ConclusionsPatients with higher preheart transplant pectoral muscle density had greater 1‐year survival. Higher pectoral LDM area was associated with decreased LOS post‐transplant and higher liver density was associated with increased LOS. These findings raise possibilities that measures of muscle density as they reflect to quality of muscle may have prognostic implications. Future studies with prospective design are needed to confirm these findings.
Comparative Performance of Different Respiratory Test Parameters for Detection of Early Respiratory Insufficiency in Patients With ALS
Kelly, Cecilia R. , Parra‐Cantu, Carolina , Thapa, Prabin , Boynton, Bradley, Selim, Bernardo J., Sorenson, Eric J. , Martinez‐Thompson, Jennifer M. , Mandrekar, Jaywant, Staff, Nathan P. , Staff, Nathan P

Mayo Clinic

Neurology | May 23, 2022 | Volume: 99 | Issue: 7 | Pages: No page available

10.1212/wnl.0000000000200758 | PMID 35584920 Get It

Inflammatory myofibroblastic tumor: A multi‐institutional study from the Pediatric Surgical Oncology Research Collaborative
Rich, Barrie S. , Fishbein, Joanna , Lautz, Timothy B. , Rubalcava, Nathan S. , Kartal, Tanvi , Newman, Erika, Wok, Pei En, Romao, Rodrigo , Polites, Stephanie F. , Løfberg, Katrine , Lascano, Danny , Davidson, Jacob , Bütter, Andreana , Short, Scott S. , Meyers, Rebecka L. , Mastropolo, Rosemarie, Weller, Jennine , Irfan, Ahmer , Rhee, Daniel S. , Riehle, Kimberly J. , Tracy, Elisabeth T. , Becktell, Kerri, Hallis, Brian, Lal, Dave R. , Li, Orville, Dal‐Soglio, Dorothé B., Piché, Nelson , Quevedo, Oswaldo Gomez, Davidoff, Andrew M. , Barber, Jo Cooke, Watters, Erin, Dasgupta, Roshni , Glick, Richard D. , Lautz, Timothy , Tracy, Elisabeth T , Dasgupta, Roshni , Whitlock, Richard S. , Naik‐Mathuria, Bindi , Kim, Eugene S. , Kastenberg, Zachary J. , Malek, Marcus M. , Utria, Alan Fremder , Rothstein, David H. , Commander, Sarah Jane , Li, Orville, Dal-Soglio, Dorothée, Murphy, Andrew J. , Watters, Erin

Mayo Clinic

International Journal of Cancer | May 23, 2022 | Volume: 151 | Issue: 7 | Pages: 1059-1067

10.1002/ijc.34132 | PMID 35604778 Get It

Abstract Inflammatory myofibroblastic tumor (IMT) is a mesenchymal neoplasm of intermediate malignancy. We describe the largest cohort of IMT patients to date, aiming to further characterize this rare, poorly understood tumor. This is a multi‐institutional review of IMT patients ≤39 years, from 2000 to 2018, at 18 hospitals in the Pediatric Surgical Oncology Research Collaborative. One hundred and eighty‐two patients were identified with median age of 11 years. Thirty‐three percent of tumors were thoracic in origin. Presenting signs/symptoms included pain (29%), respiratory symptoms (25%) and constitutional symptoms (20%). Median tumor size was 3.9 cm. Anaplastic lymphoma kinase (ALK) overexpression was identified in 53% of patients. Seven percent of patients had distant disease at diagnosis. Ninety‐one percent of patients underwent resection: 14% received neoadjuvant treatment and 22% adjuvant treatment. Twelve percent of patients received an ALK inhibitor. Sixty‐six percent of surgical patients had complete resection, with 20% positive microscopic margins and 14% gross residual disease. Approximately 40% had en bloc resection of involved organs. Median follow‐up time was 36 months. Overall 5‐year survival was 95% and 5‐year event‐free survival was 80%. Predictors of recurrence included respiratory symptoms, tumor size and distant disease. Gross or microscopic margins were not associated with recurrence, suggesting that aggressive attempts at resection may not be warranted.
ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer
Bittner, Nathan, Cox, Brett, King, Martin T. , Lawton, C.A., Orio, Peter F. , Ouhib, Zoubir , Rossi, Peter J. , Schechter, Naomi R., Davis, Brian J. , Merrick, Gregory Stephen , Showalter, Timothy N. , Small, William

Mayo Clinic

American Journal of Clinical Oncology | May 19, 2022 | Volume: 45 | Issue: 6 | Pages: 249-257

10.1097/coc.0000000000000915 | PMID 35588224 Get It

Aim/Objectives/Background: The American College of Radiology (ACR), American Brachytherapy Society (ABS), and American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for transperineal permanent brachytherapy of prostate cancer. Transperineal permanent brachytherapy of prostate cancer is the interstitial implantation of low-dose rate radioactive seeds into the prostate gland for the purpose of treating localized prostate cancer. Methods: This practice parameter was developed according to the process described under the heading The Process for Developing ACR Practice Parameters and Technical Standards on the ACR website (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters—Radiation Oncology of the Commission on Radiation Oncology, in collaboration with ABS and ASTRO. Results: This practice parameter provides a framework for the appropriate use of low-dose rate brachytherapy in the treatment of prostate cancer either as monotherapy or as part of a treatment regimen combined with external-beam radiation therapy. The practice parameter defines the qualifications and responsibilities of all involved radiation oncology personnel, including the radiation oncologist, medical physicist, dosimetrist, radiation therapist, and nursing staff. Patient selection criteria and the utilization of supplemental therapies such as external-beam radiation therapy and androgen deprivation therapy are discussed. The logistics of the implant procedure, postimplant dosimetry assessment, and best practices with regard to safety and quality control are presented. Conclusions: Adherence to established standards can help to ensure that permanent prostate brachytherapy is delivered in a safe and efficacious manner.
Editorial Comment: Hepatocellular Carcinoma Screening Guidelines Are Needed in Children With Predisposing Conditions
Hull, Nathan C.

Mayo Clinic

American Journal of Roentgenology | May 18, 2022 | Volume: 219 | Issue: 4 | Pages: 654-654

10.2214/ajr.22.27975 | PMID 35583430 Get It

Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy
Davidson, Tara M. , Foster, Nathan R. , Orme, Jacob J. , Orme, Jacob J , Lucien, Fabrice , Markovic, Svetomir N. , Dong, Haidong , Winters, Jeffrey L. , Park, Sean S.

Mayo Clinic

BMJ Open | May 17, 2022 | Volume: 12 | Issue: 5 | Pages: e050112

10.1136/bmjopen-2021-050112 | PMID 35551087 Get It

Background Patients with metastatic melanoma rely on PD-(L)1 immunotherapy, but only one-third of patients experience treatment response and all initial responders eventually develop resistance. Tumour-derived extracellular vesicles expressing Programmed death ligand 1 (evPD-L1) and soluble Programmed death ligand 1 (sPD-L1) in peripheral blood of patients with melanoma limit PD-(L)1 immunotherapy and correlate with poor survival. Therapeutic plasma exchange (TPE) removes immunosuppressive evPD-L1 and sPD-L1. We hypothesise that TPE may rescue and restore antimelanoma immunity. Methods In this two-arm study, 60 patients with metastatic melanoma progressing on checkpoint inhibition will be accrued. All patients will undergo radiotherapy on days 1–5 (at least one measurable lesion will not be irradiated) and ongoing checkpoint inhibition on day 8 and every 2–3 weeks per standard of care. Patients with baseline sPD-L1 level of ≥1.7 ng/mL and adequate clinical capacity will be enrolled in the TPE intervention arm and will undergo TPE on days 5–7, in addition to standard of care radiotherapy and immunotherapy. Other patients will remain in the standard of care arm. The primary endpoint of the study is to evaluate safety. Secondary endpoints include kinetics of sPD-L1 and evPD-L1 and clinical response by RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Study registered at ClinicalTrials.gov ( NCT04581382 ). Ethics and dissemination This trial has been approved by the Mayo Clinic Institutional Review Board. It will assess the safety and feasibility of TPE in improving outcomes for PD-(L)1 inhibitor immunotherapy in melanoma. Data will be maintained on a secure database with deidentified patient information. Data will be shared on publication in a peer-reviewed journal without the aid of professional writers. If successful, this trial will lay the ground for phase II studies that will include cancer treated with PD-(L)1 inhibitors which may benefit from TPE such as renal, bladder and lung cancers. Trial registration number NCT04581382 .
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Zhu, Mojun , Foster, Nathan R. , Hartley, Christopher , Mounajjed, Taofic, Fruth, Briant, Beamer, Staci E. , Harrington, Susan M. , Pitot, Henry C., Sanhueza, Cristobal T., Feng, Yening , Herrmann, Joerg , Huang, Bing, Bekaii‐Saab, Tanios , Wigle, Dennis A. , Ahn, Daniel H. , Hallemeier, Chris L., Yoon, Harry H. , Salomao, Marcela A, Fruth, Briant F, Feng, Yening , McWilliams, Robert R , Huang, Bing Q, Ma, Wen Wee , Dong, Haidong , Wigle, Dennis, Blackmon, Shanda , Yoon, Harry H , Bekaii-Saab, Tanios S , Chen, Chunhua , Hartley, Christopher P , Salomao, Marcela , Kim, Yohan , McWilliams, Robert R. , Lucien, Fabrice , Wee, Wen , Dong, Haidong

Mayo Clinic

Clinical Cancer Research | May 12, 2022 | Volume: 28 | Issue: 14 | Pages: 3021-3031

10.1158/1078-0432.ccr-22-0413 | PMID 35552651 Get It

Abstract Purpose: This phase Ib/2 trial investigated pembrolizumab-containing trimodality therapy in patients with gastroesophageal junction (GEJ) adenocarcinoma. Patients and Methods: Patients with GEJ adenocarcinoma (cT1–3NanyM0) received neoadjuvant pembrolizumab-containing chemoradiation (CROSS regimen) followed by surgical resection and adjuvant pembrolizumab. The primary endpoints were tolerability in the first 16 patients and pathologic complete response [pCR (ypT0N0)]. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). An independent propensity-score-matched cohort (treated with CROSS without immunotherapy) was used for comparison. Exploratory analyses included immune biomarkers in the tumor microenvironment (TME) and plasma. Results: We enrolled 31 eligible patients, of whom 29 received all expected doses of neoadjuvant pembrolizumab and 28 underwent R0 resection. Safety endpoints were met. The primary efficacy endpoint was not met [7/31 (22.6%) achieved pCR]. Patients with high [i.e., combined positive score (CPS) ≥ 10] baseline expression of programmed death (PD)-L1 in the TME had a significantly higher pCR rate than those with low expression [50.0% (4/8) vs. 13.6% (3/22); P = 0.046]. Patients with high PD-L1 expression also experienced longer PFS and OS than propensity-score-matched patients. Among trial patients with PD-L1 CPS &lt; 10, unprespecified analysis explored whether extracellular vesicles (EV) could identify further responders: an elevated plasma level of PD-L1–expressing EVs was significantly associated with higher pCR. Conclusions: Adding pembrolizumab to trimodality therapy showed acceptable tolerability but did not meet the pre-specified pCR endpoint. Exploratory analyses suggested that high PD-L1 expression in the TME and/or on EVs may identify patients most likely to achieve tumor response.